even if non-lethal or non-teratogenic, excessive levels may impair the offsprings future metabolism [132] and are associated with higher GDM risks [133]
In another embodiment, the invention provides to be used to screen and be the candidate of the substrate of treatment target of the present invention or its biologically-active moiety or the algoscopy of test compounds.In another embodiment, the invention provides to be used to screen and combine treatment target of the present invention or the candidate of its biologically-active moiety or the algoscopy of test compounds.Measure the ability of the direct combined treatment target of test compounds can be for example through said chemical compound and radiosiotope or enzymatic labelling coupling (so that chemical compound and medicine target combine and can measure through the labelled compound of labelling in the detection complex) are realized.For example, can use directly or indirectly 131 I, 125 I, 35 S, 14 C or 3 H labelled compound (for example, labeled substrate), and through the direct count of radio radiation (radioemission) or through scinticounting detection of radioactive isotope.Selectively, available for example horseradish peroxidase, alkali phosphatase or luciferase enzymatic labelling are measured composition, and detect said enzymatic labelling through measuring being converted of suitable substrate to product
Mesquita, F
mansoni : plerocercoid stage and adult stage (including immature proglottide, mature proglottide and gravid proglottide)
Construction of SUMO-LPETG-MT3 plasmid PCR amplification was used to amplify a DNA fragment containing the coding sequence of LPETG fused to the coding sequence of MT3 from the MT3-pTYB21 plasmid template (primers are listed in Additional file 1: Table S2)
